Cargando…
Short-acting β(2)-agonist prescription patterns for asthma management in the SABINA III primary care cohort
Short-acting β(2)-agonist (SABA) prescriptions and associated outcomes were assessed in 1440 patients with asthma from the SABA use IN Asthma (SABINA) III study treated in primary care. Data on asthma medications were collected, and multivariable regression models analysed the association of SABA pr...
Autores principales: | Price, David, Hancock, Kerry, Doan, Joseph, Taher, Sri Wahyu, Muhwa, Chakaya J., Farouk, Hisham, Beekman, Maarten J. H. I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522811/ https://www.ncbi.nlm.nih.gov/pubmed/36175556 http://dx.doi.org/10.1038/s41533-022-00295-7 |
Ejemplares similares
-
Over-prescription of short-acting β(2)-agonists remains a serious health concern in Kenya: results from the SABINA III study
por: Chakaya, Jeremiah, et al.
Publicado: (2023) -
Short-acting β(2)-agonist prescription patterns in patients with asthma in Turkey: results from SABINA III
por: Yorgancıoğlu, Arzu, et al.
Publicado: (2022) -
Short-acting β(2)-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study
por: Bateman, Eric D., et al.
Publicado: (2022) -
Over-prescription of short-acting β(2)-agonists for asthma in South Africa: Results from the SABINA III study
por: Smith, C, et al.
Publicado: (2022) -
A Cross-Sectional Study on Prescription Patterns of Short-Acting β(2)-Agonists in Patients with Asthma: Results from the SABINA III Colombia Cohort
por: Pedrozo-Pupo, John Carlos, et al.
Publicado: (2022)